Loading viewer...
investor_presentation
Format: PDF investor_presentation
Verona Pharma presents its Phase 3 candidate ensifentrine, a first-in-class dual PDE3/PDE4 inhibitor for COPD maintenance treatment. The presentation outlines a $10.5B US market opportunity with over 1M symptomatic patients despite dual/triple therapy, highlighting the drug's novel mechanism, demonstrated efficacy in Phase 2b trials, and favorable safety profile.
investor_presentation
27 Pages
investor_presentation
14 Pages
Richardson Wealth